PharmaMar

PharmaMar, headquartered in Madrid, Spain, is a biopharmaceutical company focused on oncology, primarily engaged in the research and development of drugs derived from marine organisms. The company is committed to discovering molecules with antitumor activity and aims to provide the medical community with new tools for cancer treatment through innovative products. PharmaMar always keeps patients in mind, continuously intensifies its research efforts, and has established itself as a world leader in the discovery of antitumor drugs originating from the ocean. PharmaMar has a robust pipeline of drug candidates and a strong oncology R&D program. The company conducts the development and commercialization of Yondelis® in Europe while also advancing various clinical-stage projects targeting multiple solid tumors, including lurbinectedin (PM1183), PM184, and PM14.